Medilytix Bureau:
Hyderabad-based vaccine manufacturer Bharat Biotech on Thursday announced that its indigenously developed COVID-19 vaccine Coavaxin is now a universal vaccine for adults and children.
Elaborating further, Bharat Biotech stated, “Our goals of developing a global vaccine against COVID-19 have been achieved and all product development for licensure has been completed.”
Earlier on Thursday, Bharat Biotech had sought from the Drugs Controller General of India regular market approval for Covaxin, which is currently only authorised for emergency use in the country, reported news agency PTI citing official sources .
In an application sent to the DCGI this week, V Krishna Mohan, Whole-Time Director at the Hyderabad-based company submitted complete information regarding chemistry, manufacturing and controls, along with pre-clinical and clinical data while seeking regular market authorisation for Covaxin.
The company, however, is yet to submit the full follow up data of clinical trial of Covaxin to DCGI, a source said.
Covaxin comprises 12 per cent of the total COVID-19 vaccine jabs administered in the country so far and it is the only vaccine that is being given to youngsters in the age-group of 15-18 years, inoculation of whom began from January 3 in the country.